^(131)I标记抗CEA单克隆抗体C50对荷人乳腺癌裸鼠局部放射免疫治疗效果  

Local radioimmunotherapy of breast cancer-bearing nude mice using anti-CEA monoclonal antibody C50 labeled with ^(131)I

作　　者：常伟勤[1] 许天敏[1] 姜瑛[1] 王心明[1] 周及彤[1] 

机构地区：[1]吉林大学第二医院肿瘤科,吉林长春130041

出　　处：《吉林大学学报（医学版）》2006年第5期822-825,共4页Journal of Jilin University：Medicine Edition

基　　金：长春市科技计划基金资助课题(10-082S06)

摘　　要：目的:观察放射免疫导向药物局部用药对荷人乳腺癌裸鼠的治疗效果。方法:将抗CEA单抗C50与131I偶联,制成放射免疫导向药物131I-C50。将已乳腺原位接种人乳腺癌MCF-7细胞且肿瘤直径已达0·5cm的裸鼠16只随机分为实验Ⅰ组、实验Ⅱ组、实验对照组(Ⅲ组)及空白对照组(Ⅳ组),每组4只。对荷人乳腺癌裸鼠进行肿瘤局部注射,Ⅰ组给予131I-C5018·5MBq,Ⅱ组给予131Ⅰ-C503·7MBq,Ⅲ组给予131I-mIgG18·5MBq,Ⅳ组给予C500·75μg,给药当日后6周内每周测定肿瘤大小,计算抑瘤率。结果:Ⅰ组和Ⅱ组与Ⅲ组之间的肿瘤体积、抑瘤率、重量比较差异有显著性(P<0·01),Ⅰ组与Ⅱ组上述指标比较差异亦具有显著性(P<0·05),Ⅲ组与Ⅳ组比较差异无显著性(P>0·05)。结论:放射性核素131I标记抗CEA单抗C50局部治疗可抑制荷人乳腺癌裸鼠肿瘤的生长。131I-C50具有潜在的临床应用价值。Objective To investigate and evaluate the curative effect of radioimmunological targeting drug on nude mice bearing breast cancer. Methods The anti CEA monoclonal antibody C50 was combined with ^131Ⅰ to produce radioimmunological targeting drug. 16 nude mice inoculated subcutaneously with breast cancer cell MCF 7 with tumor diameter about 0.5 cm were randomly into 4 groups （ n = 4） ： group Ⅰ , injected in part with ^131Ⅰ-C50 18.5 MBq; group Ⅱ , injected in part with ^131Ⅰ-C50 3. 7 MBq; group Ⅲ, injected in part with ^131Ⅰ-mIgG 18.5 MBq; group Ⅳ. injected in part with C500.75 〉g. The size of tumor volume and inhibitory rate （IR） after treatment for six weeks were calculated and compared with the control group. Results The tumor volume and curves for tumor growth and tumor weight had significant differences between group Ⅰ and the group Ⅲ as well as group Ⅱ （P〈2 0.01）; and there was significant difference between group Ⅰ and group Ⅱ （P〈20.05）, there was no significant difference between group Ⅲ and group Ⅳ （P〉0.05）. Conclusion Anti-CEA monoclonal antibody C50 labeled with radionuclide ^131Ⅰ could inhibit the growth of the tumor when given locally, ^131Ⅰ-C50 has a potential value of clinical application.

关 键 词：乳腺肿瘤 抗CEA单克隆抗体C50 ^131Ⅰ放射免疫疗法 

分 类 号：R73-352[医药卫生—肿瘤] R737.9[医药卫生—临床医学]